URGN: UroGen Pharma Ltd Kompaniya qiymatining sof foydaga nisbati

UroGen Pharma Ltd - URGN emitenti grafik logotipi

UroGen Pharma Ltd. (URGN) shaffof loyihalar portfeli va Isroil biotexnologiya firmasining malakali boshqaruviga tayanadi. Uning shaxsiy gidrogel texnologiyasi terapiyaning global miqyosda kengayishini ta'minlaydi, CMOlar orqali samarali ishlab chiqarish autsorsingi esa operatsion xatarlarni minimallashtiradi. GURU.Markets platformasidagi kompaniyaning tarixiy P/E ko'rsatkichi joriy baholash dinamikasini aks ettiradi, bunda -19.80 joriy metrika darajasini ifodalab, aktivning xavfsizlik zaxirasini aniqlash imkonini beradi.

Narx-foyda koeffitsiyenti: UroGen Pharma Ltd. (URGN) 04.07.2022 - 16.11.2026 uchun

UroGen Pharma Ltd (URGN) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- aksiya kursi va ekspertlarning narx prognozi:
- bozor kapitallashuvi haqida ma'lumot:
Kompaniyaning umumiy tahlili:URGN, UroGen Pharma Ltd
UroGen Pharma yetakchi tovari

P/E koeffitsiyenti sof foydaning bir birligining bozor qiymatini belgilaydi, bu esa investorga biznesning kelgusidagi daromadlari uchun qanchalik ortiqcha to'lov qilinganini baholash imkonini beradi. Narx-foyda koeffitsiyentini tahlil qilish orqali strateg UroGen Pharma Ltd. (URGN) kapitalizatsiya darajalarini uning ilmiy yadrosining samaradorligi va asosiy urologiya xodimlarining barqarorligi bilan solishtiradi, bu esa emitentning tijorat salohiyatining fundamental chidamliligini tasdiqlaydi.

Raqobatdosh kompaniyalar tahlili

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme Inc.)|RVMD (RevMed) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (ascentage.com)|CGON - Narx-foyda koeffitsiyenti|BCAX: Narx-foyda koeffitsiyenti|PSNL - P/E multiplikatori|Erasca Corp (ERAS) - Narxning foydaga nisbati|Delcath - Kompaniya qiymatining sof foydaga nisbati|YMAB (Y-mAbs Therapeutics Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Aura Biosciences, Inc. AURA|P/E multiplikatori CADL|P/E multiplikatori Accuray (ARAY)|Narxning foydaga nisbati SELLAS Life Sciences Group Inc. SLS|ACTU - Narx-foyda koeffitsiyenti|CTOR: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati Fate Therapeutics Corp (FATE)|Narx-foyda koeffitsiyenti WHWK|Narx-foyda multiplikatori TCRX (TScan Therapeutics, Inc.)|P/E multiplikatori CSBR|XBIT - Kapitalizatsiyaning foydaga nisbati|CEL-SCI Corporation - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati OSTX|radiopharmtheranostics.com - P/E multiplikatori|ARTV: Narxning foydaga nisbati|ANL (adlainortye.com) - Narx-foyda koeffitsiyenti|VERU - Biznesning o‘zini qoplash muddati|TPST (Tempest Therapeutics, Inc.) - P/E multiplikatori|P/E multiplikatori xiliotx.com|Narxning foydaga nisbati Enochian BioSciences (RENB)|Narxning foydaga nisbati MURA (Mural Oncology PLC)|Narxning foydaga nisbati Kairos Pharma Ltd KAPA|P/E multiplikatori OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E multiplikatori|Biznesning o‘zini qoplash muddati Curis CRIS|APLM: P/E multiplikatori|Narx-foyda koeffitsiyenti Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E multiplikatori|Genprex - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Kapitalizatsiyaning foydaga nisbati|PPBT: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Narxning foydaga nisbati|Checkpoint Therapeutics, Inc (CKPT) - P/E multiplikatori|Narxning foydaga nisbati Elevation Oncology, Inc.|ICAD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati ikenaoncology.com (IKNA)|Narxning foydaga nisbati NTBL (Notable Labs, Ltd.)|P/E multiplikatori VIRX (viracta.com)|MOR - Narx-foyda koeffitsiyenti|NAYA - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati AAPGV